Bellerophon Therapeutics (BLPH) closed at $10.04 in the latest trading session, marking a -0.4% move from the prior day. This change lagged the S&P 500's daily gain of 0.09%. Meanwhile, the Dow gained ...
Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...
Though its eponym in Greek mythology was able to successfully defeat the fire-breathing chimera, Bellerophon Therapeutics’ story is closing out on a much less victorious note. The New Jersey-based ...
Bellerophon anticipates that subsequent events and developments will cause its views to change. While Bellerophon may elect to update these forward-looking statements at some point in the future, ...
Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States WARREN, N.J., July 13, 2020 (GLOBE ...
TARRYTOWN, N.Y. — As post-lunch drowsiness settled on an auditorium full of leaders from the drug development industry, Peter Fernandes, CEO of Bellerophon Therapeutics, seized the presentation ...
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results